WO2023057893 - COMBINATION THERAPIES FOR TREATING CANCER
National phase entry:
Publication Number
WO/2023/057893
Publication Date
13.04.2023
International Application No.
PCT/IB2022/059456
International Filing Date
04.10.2022
Title **
[English]
COMBINATION THERAPIES FOR TREATING CANCER
[French]
POLYTHÉRAPIES POUR LE TRAITEMENT DU CANCER
Applicants **
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Inventors
BRUCE, Matthew
CACIOPPO, Roxanne
GUPTA, Ira
KREMER, Brandon
LIN, Jeffrey
PAKA, Prani
PALUMBO, Antonio
SHELTON, Christopher A.
Priority Data
63/252,479
05.10.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3127 | |
| EPO | Filing, Examination, Granting | 24105 | |
| Japan | Filing, Examination, Granting | 3074 | |
| South Korea | Filing, Examination, Granting | 3810 | |
| USA | Filing, Examination, Granting | 9540 |
Total:
43,656
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Disclosed herein are methods and materials for treating cancer. The present disclosure further provides methods and materials for using one or more antigen binding proteins (for example anti- B-cell maturation antigen (BCMA) antigen binding proteins) and one or more cereblon E3 ligase modulators (CELMODs) for treating a subject having cancer.[French]
L'invention concerne des méthodes et des matériels pour le traitement du cancer. La présente invention concerne en outre des méthodes et des matériels permettant d'utiliser une ou plusieurs protéines de liaison à l'antigène (par exemple des protéines de liaison à l'antigène anti-BCMA (antigène de maturation des cellules B)) et un ou plusieurs modulateurs du complexe cereblon E3 ligase (CELMOD) pour traiter un sujet atteint d'un cancer.